Side-by-side comparison

LLY vs ABBV — Side-by-side comparison

ABBV screens cheaper on EV/FCF, LLY has the higher ROIC, LLY has grown revenue faster over five years, and ABBV has the cleaner balance sheet by net debt / EBITDA.

LLY

Eli Lilly & Co.

Price

$1065.00

Market cap

$737.7B

Day %

N/A

ABBV

AbbVie Inc.

Price

$215.70

Market cap

$346.8B

Day %

N/A

Peer Comparison

Target stock against 1 market-cap comparable peer.

Heat map: red worst to green best


LLY Target	Eli Lilly & Co.	$737.7B	46.4x	43.4x	77.8%	21.6%	25.8%	N/A	N/A	N/A
ABBV	AbbVie Inc.	$346.8B	91.4x	22.8x	6.9%	6.0%	29.1%	N/A	3.7x	N/A

LLY implied-growth snapshot

Simple static valuation context using owner earnings yield and realized growth.

EV/FCF

43.4x

FCF yield

2.3%

5Y rev CAGR

21.6%

ABBV implied-growth snapshot

Simple static valuation context using owner earnings yield and realized growth.

EV/FCF

22.8x

FCF yield

5.1%

5Y rev CAGR

6.0%

5Y indexed stock chart

Static Recharts view indexed to 100 from available annual per-share data.

Quality Scorecard

Build-time composite score for LLY.

Grade C

/ 100

Quality Scorecard

Build-time composite score for ABBV.

Grade C

/ 100